Výsledky vyhledávání - "Michaela Römmele"

Akademický článek

A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors

Autor: Gabriele Manzella, Devmini C. Moonamale, Michaela Römmele, Peter Bode, Marco Wachtel, Beat W. Schäfer

Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 9, Pp 929-938 (2021)

First-line therapy for most pediatric sarcoma is based on chemotherapy in combination with radiotherapy and surgery. A significant number of patients experience drug resistance and development of relapsed tumors. Drugs that have the potential to re-s

Externí odkaz: https://doaj.org/article/f1fc0a072c4b4d0eba59315f15d35947

Zobrazit plný text záznamu

Akademický článek

Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity

Autor: Gabriele Manzella, Leonie D. Schreck, Willemijn B. Breunis, Jan Molenaar, Hans Merks, Frederic G. Barr, Wenyue Sun, Michaela Römmele, Luduo Zhang, Joelle Tchinda, Quy A. Ngo, Peter Bode, Olivier Delattre, Didier Surdez, Bharat Rekhi, Felix K. Niggli, Beat W. Schäfer, Marco Wachtel

Publikováno v: Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)

Patient-specific precision medicine approaches are important for future cancer therapies. Here, the authors show that functional drug profiling with Rhabdomyosarcoma cells isolated from PDX and primary patient tumors uncovers patient-specific vulnera

Externí odkaz: https://doaj.org/article/e1a776112ff34407a13275f886ecd3a9

Zobrazit plný text záznamu

A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors

Autor: Michaela Römmele, Devmini C. Moonamale, Peter K. Bode, Beat W. Schäfer, Marco Wachtel, Gabriele Manzella

Publikováno v: Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 9, Pp 929-938 (2021)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08c78d0a77e118c41a16f1f6e21233c5
http://europepmc.org/articles/PMC8329430

Zobrazit plný text záznamu

Abstract 3194: Development of an in vitro drug profiling platform with primary Rhabdomyosarcoma cells for tailoring patient-specific treatments

Autor: Gabriele Manzella, Luduo Zhang, Joelle Tchinda, Beat W. Schäfer, Felix Niggli, Marco Wachtel, Michaela Römmele

Publikováno v: Cancer Research. 78:3194-3194

The paradigm of cancer therapy currently shifts from broadly used cytotoxic drug cocktails to patient specific precision therapies. These novel therapies are normally directed towards tumor specific driver oncogenes, identified by genomic analysis of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::018b7e9dd49b754fccaebf7fb9a33589
https://doi.org/10.1158/1538-7445.am2018-3194

Zobrazit plný text záznamu

G3139 and Other CpG-Containing Immunostimulatory Phosphorothioate Oligodeoxynucleotides Are Potent Suppressors of the Growth of Human Tumor Xenografts in Nude Mice

Autor: Monika Baudler, James F. Beck, Carola Grebe, Uwe Pieles, Thomas Wagner, Michaela Römmele, Barbara Gonser, Hans-Peter Hofmann, Hanauer Guido, Petra Gimmnich, Volker Gekeler, C. A. Stein, Luba Benimetskaya, Thomas Maier, Sanders Karl, Astrid Leja

Publikováno v: Oligonucleotides. 16:83-93

Several phosphorothioate antisense oligodeoxynucleotides (ODN) are developed to target factors potentially involved in tumor growth and apoptosis suppression. Among them, the 18-mer G3139 (Oblimersen), which targets Bcl-2, is currently being tested i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72b76ff85aa2e814be115fa6a060efec
https://doi.org/10.1089/oli.2006.16.83

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání